Mylan Files Expedited Motion in Relation to Pioglitazone
PITTSBURGH, Oct. 23, 2012
PITTSBURGH, Oct. 23, 2012 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today
announced that it has filed an expedited motion in the U.S. District Court for
the District of Columbia to stay the Court's order related to Watson's
abbreviated new drug application (ANDA) for pioglitazone, pending appeal. The
U.S. Food and Drug Administration (FDA) joined Mylan in its motion.
Mylan CEO Heather Bresch commented, "Mylan is disappointed in yesterday's
ruling regarding pioglitazone and we believe the Court erred in its decision
by directly contravening the Hatch-Waxman Act. Mylan does not believe Watson
is entitled to participate in Mylan's 180-day exclusivity period in relation
to this product and we intend to pursue this case vigorously, including
seeking expedited relief from the appellate court if necessary."
Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately one-third of HIV/AIDS patients in developing
countries depend. We also operate one of the largest active pharmaceutical
ingredient manufacturers and currently market products in approximately 150
countries and territories. Our workforce of more than 18,000 people is
dedicated to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for it. See for
yourself. See inside. mylan.com
SOURCE Mylan Inc.
Contact: Nina Devlin (Media), +1-724-514-1968; or Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.